SepsisPhase 4NCT07556172
Clinical Study of Esketamine in Patients With Sepsis Undergoing Invasive Mechanical Ventilation
A Phase 4 study testing Esketamine and Remifentanil in people with Sepsis and Mechanical Ventilation, run by Second Affiliated Hospital of Nanchang University at 1 site in China.
Trial summary
Sepsis is a syndrome of acute organ dysfunction resulting from dysregulated host responses to infection, often leading to severe complications such as acute lung injury and ARDS. Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Sepsis, Mechanical Ventilation
- What is being tested?
- Esketamine and Remifentanil
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 80 participants
- Where
- 1 siteChina
- Study dates
- 1 Jan 2025to 30 Jun 2026
- Phase
- Phase 4
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Meet Sepsis-3.0 diagnostic criteria.
- Age ≥ 18 years.
- Required invasive mechanical ventilation.
- Expected ICU stay ≥ 24 h.
Who cannot join
- Pregnant or lactating women.
- Pregnant or lactating women.
- Child-Pugh class C or worse.
- Severe renal impairment (Scr > 178 µmol/L or BUN > 9 mmol/L).
- Pre-existing delirium, dementia, or other psychiatric disorder.
- Known allergy to opioids or benzodiazepines.
Show all 10Show fewer
- Uncontrolled hypertension (SBP > 180 mmHg or DBP > 100 mmHg).
- Preeclampsia/eclampsia.
- Significant ischemic heart disease.
- Severe pulmonary dysfunction.
Trial locations and contacts
1 site in 1 country.
China1 site
The Second Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, 330000
About this study
Official title: A Clinical Study of Esketamine for Sedation, Delirium Prevention and Clinical Outcomes in Septic Patients Under Invasive Mechanical Ventilation
Sepsis is a syndrome of acute organ dysfunction resulting from dysregulated host responses to infection, often leading to severe complications such as acute lung injury and ARDS. ICU patients on mechanical ventilation face multiple noxious stimuli and require effective analgesic and sedative treatments to improve prognosis. The limitations of existing analgesic and sedative drugs are as follows:Opioids (such as remifentanil) have strong analgesic effects but can easily cause adverse reactions such as respiratory depression, hypotension, and gastrointestinal dysfunction.Sedative drugs like midazolam may lead to delirium and gastrointestinal dysfunction.Esketamine exerts its analgesic and sedative effects by non-competitively inhibiting the N-methyl-D-aspartate (NMDA) receptor. It has sympathomimetic activity, which can reduce hemodynamic fluctuations. It also has immunomodulatory effects, which may improve the prognosis of sepsis patients. Currently, esketamine is only used for anesthesia induction in surgery, postoperative analgesia, painless procedures, and as an adjunctive treatment for depression, with limited sample sizes and few reports. There are no large-scale clinical studies on the use of esketamine in sepsis patients undergoing invasive mechanical ventilation, and further verification of its efficacy and safety is needed.
Read the detailed description
Sepsis is circulatory dysfunction or failure caused by infection. When a pathogen infects the body, the body activates autoimmune mechanisms to eliminate the pathogen. While removing pathogens, it often causes damage to its own capillary endothelium, capillary leakage, coagulation dysfunction, and local inflammatory damage. Acute lung injury is characterized by refractory hypoxemia and respiratory distress, which can further develop into more severe acute respiratory distress syndrome; Patients with pulmonary inflammation characterized by decreased lung compliance and ventilation/flow dysbivie requiring invasive mechanical ventilation to improve oxygen uptake are common in the ICU.ICU mechanically ventilated patients are in a strong stress environment, and invasive mechanically ventilated patients must experience a variety of nociceptive stimuli of different intensities in the process of receiving treatment, such as antiphysiological ventilation mode, restraint and immobilization, tracheal tube stimulation, various puncture operations, wound care, sputum suction, and environmental factors stimuli, etc., on the basis of the influence of the primary disease, these exogenous stimuli can cause strong discomfort in patients and induce severe physical and psychological stress, which is to cause patients to have anxiety, restlessness, Delirium and other important causes of adverse events (1) can even have an adverse effect on clinical prognosis. For patients with respiratory failure and strong compensatory drive for spontaneous breathing, an appropriate depth of analgesia and sedation is required to minimize the patient's excessive spontaneous respiratory drive and reduce stretch damage to lung tissue. Effective analgesia and sedation can reduce the metabolic rate of patients, reduce their oxygen consumption demand, make the changes in oxygen consumption demand of body tissues adapt to the damaged oxygen delivery state as much as possible, and reduce the metabolic burden of various organs, thereby reducing the damage caused by strong pathological factors and creating conditions for the recovery of organ function. Therefore, it is the basic task of critical care to effectively control the disease factors and various injury stimuli caused by intensive medical measures through appropriate analgesia and sedation treatment, and to maintain the comfort and safety of patients with invasive mechanical ventilation.Opioids are one of the powerful central analgesics, which have the advantages of strong analgesic effect, fast onset, strong adjustability, and low price, and are the basic drugs in the pain management of ICU patients. However, the adverse effects of opioids are mainly caused by respiratory depression, a drop in blood pressure, and a decrease in gastrointestinal motility, especially in the elderly. Thus, the use of opioids in patients with sepsis may affect their hemodynamic and gastrointestinal function.The ideal sedative, analgesic or combination regimen requires not only adequate sedation and analgesia, but also rapid onset of action, rapid awakening after discontinuation of the drug, minimal accumulation in the body and minimal circulatory impact, and anti-anxiety and anti-delirium effects. Ketamine is a commonly used anesthetic drug with good sedative and analgesic effects. However, due to the adverse reactions of the drug such as postoperative nightmares and extrapyramidal syndrome, the clinical application of the drug in the late 90s of the 20th century has decreased. Esketamine is a pure dextrarive enantiomer of ketamine, which can be used for analgesia and anesthesia in clinical practice, mainly through non-competitive inhibition of N-methyl-D-aspartate receptors to exert analgesic and sedative effects. The analgesic, sedative, and anesthetic effects of esketamine are dose-dependent, and the anesthesia has a rapid onset and relatively short duration, and its combination with benzodiazepines can greatly reduce the risk of psychotic reactions during awakening. For hemodynamically unstable mechanically ventilated patients, the use of analgesic and sedative drugs often further affects hemodynamic stability, but esketamine can inhibit the reuptake of norepinephrine by sympathetic nerve endings in the body, cause adrenergic hyperactivity, increase the concentration of norepinephrine in the circulatory system, and produce sympathomimetic activity, which can effectively reduce this adverse reaction. Moreover, esketamine does not produce respiratory drive inhibition, and patients can resume spontaneous breathing relatively early, accelerating the weaning process. In addition, esketamine has immunomodulatory effects, which can reduce the level of inflammatory factors and improve the prognosis of patients with sepsis. Therefore, esketamine in patients with sepsis who are invasively mechanically ventilated may have certain advantages in improving hemodynamics and reducing respiratory depression and gastrointestinal adverse effects.Esketamine is currently only used as an adjunct to anesthesia induction during surgery, postoperative analgesia and painless procedures, and depression, with a small sample size and few reports. There are no similar reports on its use in sepsis, so its efficacy and safety need to be further validated in randomized prospective clinical studies.
- Conditions
- Sepsis, Mechanical Ventilation
- Being tested
- Esketamine, Remifentanil
- Medical subject headings
- Sepsis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
EsketamineDrug
Also called 50mg/2ml per vial, Jiangsu Hengrui Medicine
patients received intravenous target-controlled infusion of midazolam (5mg/1ml per vial, Jiangsu Hengrui Medicine) for sedation, with a loading dose of 0.05mg/kg administered intravenously over 2 minutes, and a maintenance dose of 0.03-0.2mg/kg·h. The sedation target was a RASS score of -2 to 0. The RASS score was assessed every 4 hours, and the midazolam dose was adjusted based on the score.Esketamine (50mg/2ml per vial, Jiangsu Hengrui Medicine) was administered intravenously at a dose of 0.15-0.5mg/kg·h for analgesia. The analgesic target was a COPT (Composite Pain Scale) score of less than 3 points, and the dose of esketamine was adjusted according to the COPT score.
RemifentanilDrug
Also called 1mg per vial, Yichang Humanwell Pharmaceutical
patients received intravenous target-controlled infusion of midazolam (5mg/1ml per vial, Jiangsu Hengrui Medicine) for sedation, with a loading dose of 0.05mg/kg administered intravenously over 2 minutes, and a maintenance dose of 0.03-0.2mg/kg·h. The sedation target was a RASS score of -2 to 0. The RASS score was assessed every 4 hours, and the midazolam dose was adjusted based on the score.Remifentanil (1mg per vial, Yichang Humanwell Pharmaceutical) was administered intravenously at a dose of 0.05-2ug/kg·min for analgesia. The analgesic target was also a COPT score of less than 3 points, and the dose of remifentanil was adjusted based on the COPT score.
| Study group | Role | What they receive |
|---|---|---|
| Test group | Experimental | Both groups of patients received intravenous target-controlled infusion of midazolam (5mg/1ml per vial, Jiangsu Hengrui Medicine) for sedation, with a loading dose of 0.05mg/kg administered intravenously over 2 minutes, and a maintenance dose of 0.03-0.2mg/kg·h. The sedation target was a RASS score of -2 to 0. The RASS score was assessed every 4 hours, and the midazolam dose was adjusted based on the score.Experimental group: Esketamine (50mg/2ml per vial, Jiangsu Hengrui Medicine) was administered intravenously at a dose of 0.15-0.5mg/kg·h for analgesia. The analgesic target was a COPT (Composite Pain Scale) score of less than 3 points, and the dose of esketamine was adjusted according to the COPT score. Receives: Drug: Esketamine |
| Control group | Active comparator | Control group: Remifentanil (1mg per vial, Yichang Humanwell Pharmaceutical) was administered intravenously at a dose of 0.05-2ug/kg·min for analgesia. The analgesic target was also a COPT score of less than 3 points, and the dose of remifentanil was adjusted based on the COPT score. Receives: Drug: Remifentanil |
What is being measured
The primary outcome is the main question the study is designed to answer.
Duration of mechanical ventilation
Duration of mechanical ventilation is defined as the cumulative length of time (in hours or days) from the initiation of invasive mechanical ventilation to the first successful liberation from the ventilator for ≥48 consecutive hours, or to death, whichever occurs first
Measured: From intubation to the first successful extubation sustained for ≥48 hours, death, or Day 28, whichever occurs first
Secondary outcomes (1)
28-Day Mortality
28-day mortality is defined as the proportion of patients who die from any cause within 28 days following randomization, expressed as a percentage of the total randomized study population
Measured: From randomization to Day 28 or death, whichever occurs first
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Apr 2026
- Study start1 Jan 2025
- Primary completion30 Jun 2026 (estimated)
- Study completion30 Jun 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for SepsisStudies of the same condition, open and under way.
- More trials run by Second Affiliated Hospital of Nanchang UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- The experimental group was given escloracetam and midazolam for sedation and analgesia, while the control group was given remifentanil and midazolam for analgesia and sedation.
- Masking
- None (open label)
- Enrolment
- 80 participants (estimated)
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07556172
- Sponsor's protocol ID
- IIT-I-2025-061
- Status last verified
- Jan 2026
- First submitted
- 11 Jun 2025
- Last updated
- 29 Apr 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 29 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Clinical Study of Esketamine for Sedation, Delirium Prevention and Clinical Outcomes in Septic Patients Under Invasive Mechanical Ventilation
- ClinicalTrials.gov ID
- NCT07556172
- Acronym / sponsor ID
- IIT-I-2025-061
- Conditions
- Sepsis, Mechanical Ventilation
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 80 participants (estimated)
- Lead sponsor
- Second Affiliated Hospital of Nanchang UniversityUniversity, hospital or other
- Study start
- 1 Jan 2025 (actual)
- Primary completion
- 30 Jun 2026 (estimated)
- Study completion
- 30 Jun 2026 (estimated)
- First posted
- 29 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Sepsis is a syndrome of acute organ dysfunction resulting from dysregulated host responses to infection, often leading to severe complications such as acute lung injury and ARDS. ICU patients on mechanical ventilation face multiple noxious stimuli and require effective analgesic and sedative treatments to improve prognosis. The limitations of existing analgesic and sedative drugs are as follows:Opioids (such as remifentanil) have strong analgesic effects but can easily cause adverse reactions such as respiratory depression, hypotension, and gastrointestinal dysfunction.Sedative drugs like midazolam may lead to delirium and gastrointestinal dysfunction.Esketamine exerts its analgesic and sedative effects by non-competitively inhibiting the N-methyl-D-aspartate (NMDA) receptor. It has sympathomimetic activity, which can reduce hemodynamic fluctuations. It also has immunomodulatory effects, which may improve the prognosis of sepsis patients. Currently, esketamine is only used for anesthesia induction in surgery, postoperative analgesia, painless procedures, and as an adjunctive treatment for depression, with limited sample sizes and few reports. There are no large-scale clinical studies on the use of esketamine in sepsis patients undergoing invasive mechanical ventilation, and further verification of its efficacy and safety is needed.
Detailed description
Sepsis is circulatory dysfunction or failure caused by infection. When a pathogen infects the body, the body activates autoimmune mechanisms to eliminate the pathogen. While removing pathogens, it often causes damage to its own capillary endothelium, capillary leakage, coagulation dysfunction, and local inflammatory damage. Acute lung injury is characterized by refractory hypoxemia and respiratory distress, which can further develop into more severe acute respiratory distress syndrome; Patients with pulmonary inflammation characterized by decreased lung compliance and ventilation/flow dysbivie requiring invasive mechanical ventilation to improve oxygen uptake are common in the ICU.ICU mechanically ventilated patients are in a strong stress environment, and invasive mechanically ventilated patients must experience a variety of nociceptive stimuli of different intensities in the process of receiving treatment, such as antiphysiological ventilation mode, restraint and immobilization, tracheal tube stimulation, various puncture operations, wound care, sputum suction, and environmental factors stimuli, etc., on the basis of the influence of the primary disease, these exogenous stimuli can cause strong discomfort in patients and induce severe physical and psychological stress, which is to cause patients to have anxiety, restlessness, Delirium and other important causes of adverse events (1) can even have an adverse effect on clinical prognosis. For patients with respiratory failure and strong compensatory drive for spontaneous breathing, an appropriate depth of analgesia and sedation is required to minimize the patient's excessive spontaneous respiratory drive and reduce stretch damage to lung tissue. Effective analgesia and sedation can reduce the metabolic rate of patients, reduce their oxygen consumption demand, make the changes in oxygen consumption demand of body tissues adapt to the damaged oxygen delivery state as much as possible, and reduce the metabolic burden of various organs, thereby reducing the damage caused by strong pathological factors and creating conditions for the recovery of organ function. Therefore, it is the basic task of critical care to effectively control the disease factors and various injury stimuli caused by intensive medical measures through appropriate analgesia and sedation treatment, and to maintain the comfort and safety of patients with invasive mechanical ventilation.Opioids are one of the powerful central analgesics, which have the advantages of strong analgesic effect, fast onset, strong adjustability, and low price, and are the basic drugs in the pain management of ICU patients. However, the adverse effects of opioids are mainly caused by respiratory depression, a drop in blood pressure, and a decrease in gastrointestinal motility, especially in the elderly. Thus, the use of opioids in patients with sepsis may affect their hemodynamic and gastrointestinal function.The ideal sedative, analgesic or combination regimen requires not only adequate sedation and analgesia, but also rapid onset of action, rapid awakening after discontinuation of the drug, minimal accumulation in the body and minimal circulatory impact, and anti-anxiety and anti-delirium effects. Ketamine is a commonly used anesthetic drug with good sedative and analgesic effects. However, due to the adverse reactions of the drug such as postoperative nightmares and extrapyramidal syndrome, the clinical application of the drug in the late 90s of the 20th century has decreased. Esketamine is a pure dextrarive enantiomer of ketamine, which can be used for analgesia and anesthesia in clinical practice, mainly through non-competitive inhibition of N-methyl-D-aspartate receptors to exert analgesic and sedative effects. The analgesic, sedative, and anesthetic effects of esketamine are dose-dependent, and the anesthesia has a rapid onset and relatively short duration, and its combination with benzodiazepines can greatly reduce the risk of psychotic reactions during awakening. For hemodynamically unstable mechanically ventilated patients, the use of analgesic and sedative drugs often further affects hemodynamic stability, but esketamine can inhibit the reuptake of norepinephrine by sympathetic nerve endings in the body, cause adrenergic hyperactivity, increase the concentration of norepinephrine in the circulatory system, and produce sympathomimetic activity, which can effectively reduce this adverse reaction. Moreover, esketamine does not produce respiratory drive inhibition, and patients can resume spontaneous breathing relatively early, accelerating the weaning process. In addition, esketamine has immunomodulatory effects, which can reduce the level of inflammatory factors and improve the prognosis of patients with sepsis. Therefore, esketamine in patients with sepsis who are invasively mechanically ventilated may have certain advantages in improving hemodynamics and reducing respiratory depression and gastrointestinal adverse effects.Esketamine is currently only used as an adjunct to anesthesia induction during surgery, postoperative analgesia and painless procedures, and depression, with a small sample size and few reports. There are no similar reports on its use in sepsis, so its efficacy and safety need to be further validated in randomized prospective clinical studies.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- The experimental group was given escloracetam and midazolam for sedation and analgesia, while the control group was given remifentanil and midazolam for analgesia and sedation.
| Arm | Type | Receives |
|---|---|---|
| Test group | Experimental | Drug: EsketamineBoth groups of patients received intravenous target-controlled infusion of midazolam (5mg/1ml per vial, Jiangsu Hengrui Medicine) for sedation, with a loading dose of 0.05mg/kg administered intravenously over 2 minutes, and a maintenance dose of 0.03-0.2mg/kg·h. The sedation target was a RASS score of -2 to 0. The RASS score was assessed every 4 hours, and the midazolam dose was adjusted based on the score.Experimental group: Esketamine (50mg/2ml per vial, Jiangsu Hengrui Medicine) was administered intravenously at a dose of 0.15-0.5mg/kg·h for analgesia. The analgesic target was a COPT (Composite Pain Scale) score of less than 3 points, and the dose of esketamine was adjusted according to the COPT score. |
| Control group | Active comparator | Drug: RemifentanilControl group: Remifentanil (1mg per vial, Yichang Humanwell Pharmaceutical) was administered intravenously at a dose of 0.05-2ug/kg·min for analgesia. The analgesic target was also a COPT score of less than 3 points, and the dose of remifentanil was adjusted based on the COPT score. |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Meet Sepsis-3.0 diagnostic criteria.
- Age ≥ 18 years.
- Required invasive mechanical ventilation.
- Expected ICU stay ≥ 24 h.
Key exclusion criteria (10 listed)
- Pregnant or lactating women.
- Pregnant or lactating women.
- Child-Pugh class C or worse.
- Severe renal impairment (Scr > 178 µmol/L or BUN > 9 mmol/L).
- Pre-existing delirium, dementia, or other psychiatric disorder.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| EsketamineAlso: 50mg/2ml per vial, Jiangsu Hengrui Medicinepatients received intravenous target-controlled infusion of midazolam (5mg/1ml per vial, Jiangsu Hengrui Medicine) for sedation, with a loading dose of 0.05mg/kg administered intravenously over 2 minutes, and a maintenance dose of 0.03-0.2mg/kg·h. The sedation target was a RASS score of -2 to 0. The RASS score was assessed every 4 hours, and the midazolam dose was adjusted based on the score.Esketamine (50mg/2ml per vial, Jiangsu Hengrui Medicine) was administered intravenously at a dose of 0.15-0.5mg/kg·h for analgesia. The analgesic target was a COPT (Composite Pain Scale) score of less than 3 points, and the dose of esketamine was adjusted according to the COPT score. | Drug | Test group |
| RemifentanilAlso: 1mg per vial, Yichang Humanwell Pharmaceuticalpatients received intravenous target-controlled infusion of midazolam (5mg/1ml per vial, Jiangsu Hengrui Medicine) for sedation, with a loading dose of 0.05mg/kg administered intravenously over 2 minutes, and a maintenance dose of 0.03-0.2mg/kg·h. The sedation target was a RASS score of -2 to 0. The RASS score was assessed every 4 hours, and the midazolam dose was adjusted based on the score.Remifentanil (1mg per vial, Yichang Humanwell Pharmaceutical) was administered intravenously at a dose of 0.05-2ug/kg·min for analgesia. The analgesic target was also a COPT score of less than 3 points, and the dose of remifentanil was adjusted based on the COPT score. | Drug | Control group |
Primary outcome
Duration of mechanical ventilation
Time frame: From intubation to the first successful extubation sustained for ≥48 hours, death, or Day 28, whichever occurs first
Duration of mechanical ventilation is defined as the cumulative length of time (in hours or days) from the initiation of invasive mechanical ventilation to the first successful liberation from the ventilator for ≥48 consecutive hours, or to death, whichever occurs first
1 secondary outcome
28-Day Mortality
Time frame: From randomization to Day 28 or death, whichever occurs first
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Apr 2026.
- Individual participant dataSharing planned: Yes
Related trials for Sepsis
Not yet recruitingPhase 2/3
A Pivotal Safety and Immunogenicity GBS-NN/NN2 Vaccine Maternal Immunisation Trial
Streptococcus Agalactiae Infection, Neonatal Sepsis
Active, not recruiting
CT for Personalized Mechanical Ventilation
Ventilator-Induced Lung Injury, Sepsis Syndrome
RecruitingPhase 4
A Study to Compare the Efficacy and Safety of Extended and Intermittent Infusion of Beta-lactams in Critically Ill Paediatric Patients
Infection, Sepsis
Not yet recruiting
Double Plasma Separation and Adsorption in Acute-on-Chronic Liver Failure (DPMAS-ACLF Trial)
Acute-on-Chronic Liver Failure (ACLF)
Active, not recruitingPhase 4
Thymosin Alpha 1 and IgM Levels in Sepsis
Sepsis, Septic Shock
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Esketamine and Remifentanil in people with Sepsis and Mechanical Ventilation, run by Second Affiliated Hospital of Nanchang University at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 29 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Duration of mechanical ventilation (time frame: From intubation to the first successful extubation sustained for ≥48 hours, death, or Day 28, whichever occurs first). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Apr 2026.